Inmune Bio Inc (INMB) Stock Price, Quote & News

Company Profile

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of b...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 964 3720

Website: www.inmunebio.com

Address:

225 NE Mizner Blvd., Suite 640, Boca Raton, United States

htpntg Jan. 6 at 3:18 PM

$INMB i am thinking about opening a position in this. Just wanted clarification on nasdaq compliance, have they recived any letters or anything ? I couldnt find anything on it potential delistings. Whats there cash balance, and how long is tge runway ? Basically hpw likey are they to dilute to raise money. Any potential stock splits etc. And finally keys events coming up and dates to look fowards to.

1 · Reply

insideguys123 Jan. 5 at 8:43 PM

$INMB How is the stock at an all time low when the company is closer than they have ever been to an approval?

1 · Reply

10baggerPete Jan. 3 at 7:56 PM

$INMB 2026 = New Beginning 🔥Prepare to be Dazzled.

1 · Reply

Nessi_1 Jan. 1 at 10:52 PM

$ETH.X $GASS.X $INMB $PEPE.X

0 · Reply

Vladdavceo Dec. 31 at 6:09 PM

$GASS.X $ETH.X $PEPE.X $INMB

0 · Reply

SuperGreenToday Dec. 30 at 5:56 AM

$INMB Share Price: $1.65 Contract Selected: Jun 18, 2026 $0.5 Calls Buy Zone: $0.96 – $1.18 Target Zone: $1.80 – $2.20 Potential Upside: 77% ROI Time to Expiration: 170 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

10baggerPete Dec. 29 at 9:27 PM

$INMB Hos Shite

0 · Reply

alexx013 Dec. 29 at 5:48 PM

$INMB adding @ 1.64

0 · Reply

AetherArtisan Dec. 26 at 5:03 PM

$INMB Expectations are recalibrating toward pragmatic delivery instead of lofty projections. Improving execution cadence across quarters would alter sentiment materially. Clear execution would attract broader institutional participation. Durable value creation requires execution to catch up with vision.

0 · Reply

NachoBusiness Dec. 24 at 4:21 PM

$INMB shorted right back down , can’t hold gains

0 · Reply

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio's CORDStrom™ Platform

Dec 1, 2025, 8:00 AM EST - 5 weeks ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595's Evidence Base in High-Inflammation Alzheimer's Patients

Nov 18, 2025, 8:00 AM EST - 7 weeks ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Oct 30, 2025, 11:16 PM EDT - 2 months ago

INmune Bio, Inc. (INMB) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 4:05 PM EDT - 2 months ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Oct 14, 2025, 7:00 AM EDT - 3 months ago

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Aug 8, 2025, 3:23 PM EDT - 5 months ago

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 8:00 AM EDT - 5 months ago

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

Jul 31, 2025, 7:00 AM EDT - 5 months ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Jul 29, 2025, 7:00 AM EDT - 5 months ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

Jul 4, 2025, 11:48 PM EDT - 6 months ago

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

Jul 4, 2025, 9:20 AM EDT - 6 months ago

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday

Jun 30, 2025, 4:05 PM EDT - 6 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 30, 2025, 11:52 AM EDT - 6 months ago

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

Jun 30, 2025, 7:36 AM EDT - 6 months ago

INmune Bio's Alzheimer's drug fails to meet main goal in mid-stage study

Jun 30, 2025, 7:30 AM EDT - 6 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer's Disease

Jun 27, 2025, 4:50 PM EDT - 6 months ago

INmune Bio: Finding Pay Dirt In Alzheimer's?

Jun 27, 2025, 12:16 PM EDT - 6 months ago

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 27, 2025, 10:38 AM EDT - 6 months ago

INmune Bio Stock Soars Friday On Alzheimer's Treatment Hopes

Jun 26, 2025, 4:00 PM EDT - 6 months ago

INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th

Jun 16, 2025, 11:29 AM EDT - 7 months ago

INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity

May 15, 2025, 5:28 PM EDT - 8 months ago

INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity

May 10, 2025, 3:57 AM EDT - 8 months ago

INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:10 PM EDT - 8 months ago

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 8 months ago

INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th

Apr 14, 2025, 8:00 AM EDT - 9 months ago

INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness

Mar 27, 2025, 8:15 PM EDT - 10 months ago

INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:05 PM EDT - 10 months ago

INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update

Mar 21, 2025, 1:15 PM EDT - 10 months ago

Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +

PNW PRI

Mar 18, 2025, 4:31 PM EDT - 10 months ago

INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results

Feb 12, 2025, 7:00 AM EST - 11 months ago

INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer

Feb 10, 2025, 7:00 AM EST - 11 months ago

INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jan 2, 2025, 8:52 AM EST - 1 year ago

INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025

Dec 30, 2024, 3:20 PM EST - 1 year ago

INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers

Dec 4, 2024, 9:00 AM EST - 1 year ago

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower

Oct 31, 2024, 8:09 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

Oct 28, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB

Oct 24, 2024, 3:03 PM EDT - 1 year ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Oct 24, 2024, 9:30 AM EDT - 1 year ago

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024

Oct 11, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit

Sep 30, 2024, 5:04 AM EDT - 1 year ago

INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal

Sep 26, 2024, 8:00 AM EDT - 1 year ago

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort

Sep 17, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints

Sep 13, 2024, 8:30 AM EDT - 1 year ago

INmune Bio Announces $13.0 Million Registered Direct Offering

Sep 3, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference

Aug 1, 2024, 11:50 PM EDT - 1 year ago

INmune Bio, Inc. (INMB) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 1 year ago

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update

Jul 29, 2024, 9:00 AM EDT - 1 year ago

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer's Patients

Jul 25, 2024, 8:00 AM EDT - 1 year ago

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024

htpntg Jan. 6 at 3:18 PM

1 · Reply

insideguys123 Jan. 5 at 8:43 PM

$INMB How is the stock at an all time low when the company is closer than they have ever been to an approval?

1 · Reply

10baggerPete Jan. 3 at 7:56 PM

$INMB 2026 = New Beginning 🔥Prepare to be Dazzled.

1 · Reply

Nessi_1 Jan. 1 at 10:52 PM

$ETH.X $GASS.X $INMB $PEPE.X

0 · Reply

Vladdavceo Dec. 31 at 6:09 PM

$GASS.X $ETH.X $PEPE.X $INMB

0 · Reply

SuperGreenToday Dec. 30 at 5:56 AM

0 · Reply

10baggerPete Dec. 29 at 9:27 PM

$INMB Hos Shite

0 · Reply

alexx013 Dec. 29 at 5:48 PM

$INMB adding @ 1.64

0 · Reply

AetherArtisan Dec. 26 at 5:03 PM

0 · Reply

NachoBusiness Dec. 24 at 4:21 PM

$INMB shorted right back down , can’t hold gains

0 · Reply

alexx013 Dec. 23 at 7:03 PM

$INMB adding @ 1.73

0 · Reply

Pkinla Dec. 23 at 3:15 AM

$INMB good things coming with fda eop2 early 26!

1 · Reply

lisaparsons Dec. 21 at 3:55 AM

$INMB offering. Time to sell for loss fm

2 · Reply

Djdanny Dec. 16 at 4:21 PM

$INMB $ORGO STRONG BUY ❤️The FDA confirmed that the ReNu clinical development program, which includes two large Phase 3 randomized controlled trials (RCT), a separate 200-patient study, and extensive commercial history, is appropriate for BLA submission. Organogenesis expects to initiate the rolling BLA before the end of December 2025.

0 · Reply

NachoBusiness Dec. 15 at 2:50 PM

$INMB Volume is nothing, any drop is manupulation.

0 · Reply

OptionWave1 Dec. 12 at 2:55 PM

$INMB next leg up starting

1 · Reply

NachoBusiness Dec. 11 at 9:14 PM

$INMB crap day

1 · Reply

kyra_liu1 Dec. 10 at 10:27 PM

$INMB continues to move. Up to 2.27 from my 1.52 alert

2 · Reply

OptionWave1 Dec. 10 at 10:11 PM

$INMB big news. Can see 2.5 by Friday.

0 · Reply

DARKP00L Dec. 10 at 9:55 PM

$INMB 16:53 on Dec. 10 2025 INmune Bio Terminates $75M At-the-Market Sales Agreement With RBC Capital Markets And BTIG, Effective December 19, 2025; Prior To Termination, The Co Issued And Sold 1,353,469 Shares Of Common Stock Under The Sales Agreement, Raising Net Proceeds Of ~$10.5M #tradeideas

2 · Reply

None_ Dec. 9 at 9:50 PM

$NWBO $INMB Both failures.

2 · Reply

daybaron Dec. 9 at 7:34 PM

$INMB like the 3x daily volume and big blocks being traded,

0 · Reply

Market Cap	40.94M
Revenue (ttm)	10,000.00
Net Income (ttm)	-42.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-420,800.03%
Debt to Equity Ratio	0.00

Volume	322,500
Avg Vol	427,958
Day's Range	N/A - N/A
Shares Out	26.59M
Stochastic %K	23%
Beta	0.70
Analysts	Sell
Price Target	$7.50